Acitretine antenatal infection

Acitretine Antenatal Infection is a medical condition that arises due to the exposure of a fetus to Acitretine, a second-generation retinoid. Acitretine is primarily used in the treatment of severe psoriasis and other skin disorders. However, its use during pregnancy is strongly discouraged due to its teratogenic effects, which can lead to Acitretine Antenatal Infection.

Overview[edit | edit source]

Acitretine is a systemic retinoid, the major metabolite of etretinate. It is used in the treatment of severe psoriasis and other severe skin disorders. Acitretine is not recommended for use during pregnancy due to its teratogenic effects. It is known to cause serious birth defects in a developing fetus. The condition that arises due to the exposure of a fetus to Acitretine is referred to as Acitretine Antenatal Infection.

Teratogenic Effects[edit | edit source]

The teratogenic effects of Acitretine are severe and can lead to various birth defects. These include craniofacial, cardiac, thymic and central nervous system malformations. The risk of these defects is particularly high during the first trimester of pregnancy, but exposure at any point during pregnancy can lead to adverse effects.

Prevention and Management[edit | edit source]

Prevention of Acitretine Antenatal Infection primarily involves avoiding the use of Acitretine during pregnancy. Women of childbearing age who are prescribed Acitretine should be counseled about the risks and should use effective contraception during treatment and for a period after discontinuing treatment. In cases where exposure has occurred, management involves a detailed fetal assessment to identify any potential malformations or complications.